BioSpace News Archive

Ring Therapeutics hopes to bring in a “new era of gene therapies” to rise above the challenges of current options. A cohort of investors bought into the hope with a $117 million Series B funding round.

A breakthrough study has found that altering the genetic makeup of malaria-carrying mosquito species could be the key to stopping the spread of the malaria virus and finally eradicating the disease.

The extension will see a new investment of nearly $1 billion, which AbbVie and Calico will split down the middle.

The research will focus on accelerating the capacities of BLU-222, an investigational therapy that Blueprint designed to target cyclin-dependent kinase 2 (CDK2).

Three companies, including two biotech companies and one drug discovery company, announced yesterday the successful closing of Series A financing, with IMIDomics taking the lead.

The global clinical rollators market has witnessed steady growth over the years with the rising technological advancements in developing rollator walker with lightweight and seat rollators.

LivaNova PLC, a market-leading medical technology and innovation company, reported results for the quarter ended June 30, 2021.

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, announced that it will report its second quarter 2021 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 11, 2021.

BioCryst Pharmaceuticals, Inc. announced that the company has appointed hereditary angioedema and rare disease industry leader, Vincent Milano, to its board of directors.

TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the company will report second quarter 2021 financial results on Wednesday, August 11, 2021.